alongside 
a multi-center trial5 for lung cancer. Results from 
the Phase 3 trials are expected over the next 
three years. Investing in the future of PT remains a priority for 
IBA. December saw the announcement of a 
research collaboration with the University of 
Kansas Medical Center (KUMC), focused on 
preclinical 
research 
in 
the 
use 
of 
ConformalFLASH6 technology. This builds on 
the existing relationship between IBA and 
KUMC, who had previously published a joint 
abstract on FLASH te